Sagimet Biosciences   Report issue

For profit Phase 2
Founded: Palo Alto CA United States (2006)

Organization Overview

First Clinical Trial
2013
NCT02223247
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

3V Biosciences, Inc.

Active Ingredients

Drugs in Phase 2 Trials (2)

3-v bioscience-2640 (1 trial)

tvb-2640 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Liver Diseases (Phase 2)

Metabolic Syndrome (Phase 2)

Neoplasms (Phase 1)

Non-alcoholic Fatty Liver Disease (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2